Xcell Therapeutics

엑셀세라퓨틱스 · 373110

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$18.5M (₩25.5B)

Overview

Xcell Therapeutics makes cell culture media, the nutrient solutions that keep living cells alive and growing, used in the development and manufacture of cell and gene therapies, a class of advanced biologic medicines.

Its products supply biotech and pharmaceutical companies working on cell therapy, gene therapy, and gene-modified cell therapy. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company is expanding its media portfolio beyond therapeutic use into cultivated-meat ingredients and functional cosmetic raw materials.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$1.4M

▲ +0.8% YoY

Operating profit · FY2025

−US$7.9M

Loss widened

Net income · FY2025

−US$7.9M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$814.4K(₩1.1B)	US$1.4M(₩1.9B)	US$1.4M(₩1.9B)
Operating profit	−US$6.3M(−₩8.7B)	−US$6.8M(−₩9.3B)	−US$7.9M(−₩10.9B)
Net income	−US$6.7M(−₩9.3B)	−US$6.9M(−₩9.5B)	−US$7.9M(−₩10.9B)

Revenue

FY2023US$814.4K
FY2024US$1.4M
FY2025US$1.4M

Operating profit

FY2023−US$6.3M
FY2024−US$6.8M
FY2025−US$7.9M

Net income

FY2023−US$6.7M
FY2024−US$6.9M
FY2025−US$7.9M

Key ratios (FY2025)

ROE

-153.1%

Debt/Eq

120.3%

Op. margin

-556.8%

Net margin

-560.6%

Rev. YoY

▲ +0.8%

Why it matters

The filing notes that most cell culture media used in Korea is currently imported, and Xcell Therapeutics has focused on domestic development of this material since its founding.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?